As an alternative approach, we employed the thalidomide derivative lenalidomide, which has been shown to induce the proteasomal degradation of IKZF3 (and IKZF1) and is used therapeutically in treating multiple myeloma (28–30). This evidence concerns the gene IKZF1 and plasma cell myeloma.